Tizanidine Discontinuation
If tizanidine needs to be discontinued in patients who have been using it long-term, the dose must be tapered slowly to prevent withdrawal symptoms including rebound hypertension, tachycardia, and hypertonia.
Why Slow Tapering is Critical
Tizanidine is an α2-adrenergic receptor agonist (a clonidine derivative) that suppresses norepinephrine release. Abrupt cessation causes a rebound surge in sympathetic activity, leading to potentially dangerous withdrawal symptoms 1. The FDA label explicitly warns that therapy discontinuation, especially in patients on high doses for prolonged periods, requires gradual dose reduction 2.
Documented Withdrawal Symptoms Include:
- Cardiovascular: Hypertension (including hypertensive emergency with BP 250/145 mmHg), tachycardia 3, 4
- Neuromuscular: Increased muscle spasm/tone, hypertonia, tremor 2
- Psychiatric: Anxiety, agitation, altered mental status 3
- Other: Diaphoresis, severe body aches 4
Recommended Tapering Approach
Use a hyperbolic (proportionate) dose reduction strategy rather than linear reductions. While the specific taper schedule for tizanidine is not explicitly defined in guidelines, the pharmacological principle is clear: reduce by approximately 5-10% of the most recent dose every 2-4 weeks 1.
Why Hyperbolic Tapering?
The relationship between drug dose and receptor activity is hyperbolic—not linear. Linear reductions (e.g., cutting 2 mg every week) produce increasingly large pharmacological changes as you approach zero, which explains why withdrawal symptoms often worsen at lower doses. Proportionate reductions maintain consistent pharmacological decrements 5.
Practical Implementation:
- Higher doses: May tolerate faster reductions (e.g., 10% every 2 weeks)
- Lower doses: Require slower, smaller reductions (e.g., 5% every 3-4 weeks)
- Final doses: May need to be very small (< 1 mg) before complete discontinuation
- If withdrawal emerges: Revert to the previous tolerated dose and slow the taper further 2
Special Considerations
High-Risk Patients Requiring Extra Caution:
- Patients on high doses for extended periods (>2 years) 3
- Those with suspected misuse or dependence 2, 3
- Patients with cardiovascular disease (withdrawal can precipitate hypertensive crisis) 3
- Elderly patients or those with hepatic/renal dysfunction 2
Alternative Bridging Strategy:
If tizanidine withdrawal proves intolerable despite slow tapering, consider cross-tapering to oral clonidine (0.1 mg TID, then taper over 5+ days) or using a clonidine patch for more stable blood levels during the transition 3. This leverages the shared α2-agonist mechanism while providing smoother pharmacokinetics.
Common Pitfalls to Avoid
- Never stop abruptly—even "low" doses can cause withdrawal after chronic use
- Don't use fixed linear reductions—they become progressively more difficult to tolerate
- Don't rush the taper—months to years may be necessary for long-term users
- Don't ignore early withdrawal signs—hypertension and tachycardia are red flags requiring dose adjustment
- Don't assume all muscle relaxants taper the same—tizanidine's α2-agonist mechanism creates unique withdrawal risks similar to clonidine, unlike other muscle relaxants
Monitoring During Discontinuation
Track these parameters at each dose reduction:
- Blood pressure and heart rate (most sensitive indicators)
- Muscle tone/spasticity (reason for original prescription)
- Subjective withdrawal symptoms (anxiety, agitation, body aches)
- Sleep quality (often disrupted during withdrawal)
The perioperative context is different: Tizanidine should be continued through surgery including the day of operation due to withdrawal risks 1. Elective discontinuation is a separate decision requiring the gradual approach outlined above.